Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
Recruiting · NCT06375161 · Registry updated 2024-04-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. | B Cell Malignancies | Recruiting | Early phase 1 | 2024-04-19 | NCT06375161 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Tongji Hospital, Tongji University School of Medicine | 23 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shanghai Tongji Hospital | Shanghai | China | 1 |